FrancophonIA/ELRC3.0 huggingface dataset:
English: As elvitegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis.
Maltese: Billi elvitegravir jeħel ħafna mal-proteini tal-plażma, mhux mistenni li se jitneħħa b'mod sinifikanti permezz ta' emodijalisi jew dijalisi peritoneali.
English: a The difference in proportions and its 95% CIs between randomised treatment groups is based on normal approximation.
Maltese: Id-differenza fil-proporzjonijiet u fin-95% CIs tagħhom bejn il-gruppi tat-trattament magħżula b'mod każwali hi bbażata
English: Female patients of childbearing potential should use either a hormonal contraceptive containing at least 30 µg ethinylestradiol and containing norgestimate as the progestagen or should use an alternative reliable method of contraception (see sections 4.5 and 4.6).
Maltese: Pazjenti nisa li jista' jkollhom it-tfal għandhom jużaw jew kontraċettiv ormonali li jkun fih mill-inqas 30 µg ta' ethinylestradiol u li jkun fih norgestimate bħala l-progestagen jew għandhom jużaw metodu affidabbli alternattiv ta' kontraċezzjoni (ara sezzjonijiet 4.5 u 4.6).
English: Elvitegravir (antacid suspension given ± 4 hours from elvitegravir administration): AUC: ↔
Maltese: Il-frekwenza ta' dan il-mard mhijiex magħrufa (ara sezzjoni 4.4).
English: Co-administration of Vitekta with medicinal products that are strong inducers of CYP3A is contraindicated as the expected decrease in plasma concentrations of elvitegravir can lead to loss of therapeutic effect and possible development of resistance to elvitegravir (see section 4.3).
Maltese: L-għoti ta' Vitekta ma' prodott mediċinali li huma indutturi qawwija ta' CYP3A hu kontraindikat għax it-tnaqqis mistenni fil-konċentrazzjonijiet ta' elvitegravir fil-plażma jista' jwassal għat-telf taleffett terapewtiku u l-iżvilupp possibbli ta' reżistenza għal elvitegravir (ara sezzjoni 4.3).
English: No dose adjustment is required when Vitekta is co-administered with zidovudine.
Maltese: Ir-rilevanza in vivo ta' dawn l-interazzjonijiet mhijiex ċara.
English: United Kingdom Gilead Sciences Ltd Tel: + 44 (0) 8000 113 700
Maltese: Tel: + 46 (0) 8 5057 1849 United Kingdom Gilead Sciences Ltd Tel: + 44 (0) 8000 113 700
English: Cambridge
Maltese: Warfarin
English: No clinically relevant pharmacokinetic differences due to gender have been identified for boosted
Maltese: L-ebda differenza farmakokinetika klinikament rilevanti minħabba s-sess ma ġiet identifikata għal
English: • antacids, used to treat heartburn or acid reflux, such as aluminium/magnesium hydroxide or calcium carbonate (see also section 3 of this leaflet)
Maltese: • antaċidi, li jintużaw biex jittrattaw ħruq ta' istonku jew ir-rifluss tal-aċidu, bħal aluminium/magnesium hydroxide jew calcium carbonate (ara wkoll sezzjoni 3 ta' dan il-fuljett)
English: Physicians should refer to current HIV treatment guidelines for the optimal management of HIV infection in patients co-infected with hepatitis B virus (HBV).
Maltese: It-tobba għandhom jirreferu għal-linji gwida kurrenti tat-trattament ta' l-HIV għall-aħjar immaniġġjar ta' infezzjoni bl-HIV f'pazjenti li huma infettati ukoll bil-virus ta' l-epatite B (HBV).
English: Further dose reduction of rifabutin has not been studied.
Maltese: Tnaqqis addizzjonali fid-doża ta' rifabutin ma ġiex studjat.
English: When used in combination with atazanavir/ritonavir and lopinavir/ritonavir, the dose of Vitekta should be decreased from 150 mg once daily to 85 mg once
Maltese: Meta tintuża flimkien ma' atazanavir/ritonavir u lopinavir/ritonavir, id-doża ta' Vitekta għandha titnaqqas minn 150 mg darba kuljum għal 85 mg darba
English: It is recommended that the international normalised ratio (INR) be monitored upon co-administration of Vitekta.
Maltese: Hu rakkomandat li l-proporzjon normalizzat internazzjonali (INR) jiġi mmonitorjat meta jingħata flimkien ma' Vitekta.
English: • If you have liver problems or a history of liver disease, including hepatitis.
Maltese: • Jekk għandek problemi fil-fwied jew kellek passat mediku ta' mard tal-fwied, li jinkludi lepatite.
English: (may affect 1 to 10 in every 100 patients treated)
Maltese: (jistgħu jaffettwaw minn 1 sa 10 minn kull 100 pazjent li jkunu ttrattati)
English: Exp <<EXP month/year>>
Maltese: Jiskadi <<EXP month/year>>
English: Chemotherapy 63, 733
Maltese: J Antimicrob. Chemotherapy 63, 733
English: 8 Meijer et al, Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves, Vet. Quart.
Maltese: Meijer et al, Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves, Vet.
English: 4.3 Contraindications
Maltese: 4.3 Kontra indikazjonijiet
English: Haemophilus paragallinarium and Bordetella avium.
Maltese: Haemophilus paragallinarium u Bordetella avium.
English: Arcanobacterium pyogenes, Histophilus somni and Mycoplasma spp.
Maltese: Arcanobacterium pyogenes, Histophilus somni u Mycoplasma spp.
English: For a full list of excipients, see section 6.1.
Maltese: Għal lista sħiħa ta' ingredjenti (mhux attivi), ara t-taqsima 6.1.
English: Store below 25 ºC.
Maltese: Aħżen f'anqas minn 25 ºC.
English: 4941 VX Raamsdonksveer The Netherlands research@dopharma.com
Maltese: 4941 VX Raamsdonksveer L-Olanda research@dopharma.com
English: Annex I
Maltese: NUMRU(I)
English: • Pleuropneumonia caused by Actinobacillus pleuropneumoniae.
Maltese: • Plewropnewmonja kkawżata minn Actinobacillus pleuropneumoniae.
English: Pharmacotherapeutic group: Antibacterial for systemic use, tetracyclines ATCvet-code: QJ01AA02
Maltese: Antibatterjali għal użu sistemiku, Kodiċi ATĊ veterinarja: QJ01AA02
English: 14 F. J. Angulo et al., Evidence of an Association Between Use of Anti-microbial Agents in Food Animals and Antimicrobial Resistance Among Bacteria Isolated from Humans and the Human Health Consequences of Such Resistance, J. Vet. Med.. 51: 374 - 379
Maltese: Angulo et al., Evidence of an Association Between Use of Anti-microbial Agents in Food Animals and Antimicrobial Resistance Among Bacteria Isolated from Humans and the Human Health Consequences of Such Resistance, J.
English: Doxycycline is a semi-synthetic tetracycline antibiotic.
Maltese: Doxycycline huwa antibijotiku tetraċiklin semi-sintetiku.
English: afl.
Maltese: OĦRA
English: 4941 VX Raamsdonksveer The Netherlands
Maltese: 4941 VX Raamsdonksveer L-OLANDA
English: Treatment was considered to have been effective in 98% of calves treated with Ronaxan (n=361) compared to 85% of calves treated with reference antimicrobial products (n=174).
Maltese: Il-kura kienet meqjusa li kienet effettiva fi 98% tal-għoġġiela li rċevew kura b'Ronaxan (n=361) meta mqabbla ma' 85% tal-għoġġiela li rċevew kura bi prodotti antimikrobjali ta' referenza (n=174).
English: 9 (1983) 2 George et al, Comparison of therapeutic efficacy of doxycycline, chlortetracycline and lincomycin-spectinomycin on E.
Maltese: George et al, Comparison of therapeutic efficacy of doxycycline, chlortetracycline and lincomycin-spectinomycin on E. coli infection of young chickens.
English: = .... mg product per litre drinking water
Maltese: = .... mg ta' prodott għal kull litru ta' ilma taxxorb
English: • Enteritis caused by Clostridium perfringens and Clostridium colinum.
Maltese: • Enterite kkawżata minn Clostridium perfringens u Clostridium colinum.
English: 7 The ARBAO-II study, Occurrence of antimicrobial resistance among bacterial pathogens and indicator bacteria in pigs in different European countries form year 2002-2004, Acta Veterinaria Scandinavica 50(19) (2008)
Maltese: 7 L-Istudju ARBAO-II, L-okkorrenza ta' reżistenza antimikrobjali fost il-patoġeni batteriċi u l-batterji nidikaturi fil-majjali f'pajjiżi Ewropej differenti mis-snin 2002-2004, Acta Veterinaria Scandinavica 50(19) (2008)
English: The MIC90s values ranged from 0.03 μg/ml for Mycoplasma hyopneumoniae to 0.5 μg/ml for P. multocida.
Maltese: Il-valuri tal-MIC90s kienu jvarjaw minn 0.03 μg/ml għal Mycoplasma hyopneumoniae sa 0.5 μg/ml għal P. multocida.
English: Diergeneeskd., 119 (1), 17 (1994) 12 Gool et al, Caracteristiques pharmacocinetiques et bilan des essays cliniques pour le traitement ou la metaphylaxe des bronchopneumonies infectieuses des veaux par le roxanan, Proc. 14th World Congr.
Maltese: Gool et al, Caracteristiques pharmacocinetiques et bilan des essays cliniques pour le traitement ou la metaphylaxe des bronchopneumonies infectieuses des veaux par le roxanan, Proc. 14th World Congr.
English: • Infections of the respiratory tract caused by Mycoplasma spp., Escherichia coli,
Maltese: • Infezzjonijiet tal-apparat respiratorju kkawżati minn Mycoplasma spp., Escherichia coli,
English: Steady state plasma levels for doxycycline ranged from 0.37 - 0.89 μg/ml (at 7 mg/kg body weight), 0.7 to 1.14 μg/ml (at 13 mg/kg body weight) and 1.62 to 3.18 μg/ml (at 26 mg/kg body weight).
Maltese: Il-livelli fi stat stabbli fil-plażma għal doxycycline varjaw minn 0.37 - 0.89 μg/ml (f'doża ta' 7 mg/kg tal-piż tal-ġisem), 0.7 sa 1.14 μg/ml (f'doża ta' 13 mg/kg tal-piż tal-ġisem) u 1.62 sa 3.18 μg/ml (f'doża ta' 26 mg/kg tal-piż tal-ġisem).
English: Two literature references reported that doxycycline at 50 mg per litre in drinking water for 3 - 5 days was effective in treating challenge infections with E. coli (George, 19772) and E. coli and M. gallisepticum (Migaki, 19773).
Maltese: Żewġ referenzi fil-letteratura rrapportaw li doxycycline f'doża ta' 50 mg kull litru fl-ilma tax-xorb għal 3 - 5 ijiem kien effettiv fil-kura ta' infezzjonijiet bi sfida bl-E. coli (George, 19772) u bl-E. coli u M. gallisepticum (Migaki, 19773).
English: Doxycycline inhibits bacteria, Mycoplasma, Chlamydia, Rickettsia, and certain Protozoa.
Maltese: Id-doxycycline tinibixxi l-batterji, Mycoplasmata, Chlamydia, Rickettsia, u ċerti Protozoa.
English: • Atrophic rhinitis caused by Pasteurella multocida and Bordetella bronchiseptica
Maltese: • Rinite atrofika kkawżata minn Pasteurella multocida u Bordetella bronchiseptica
English: Tetracyclines can chelate cations (e.g. Mg, Mn, Fe and Al) and this may lead to decreased bioavailability.
Maltese: It-tetracyclines jistgħu jagħmlu kelazzjoni tal-cations (eż. Mg, Mn, Fe u Al) u dan jista' jwassal għal biodisponibilità mnaqqsa.
English: Greece
Maltese: Bulgarija
English: Chickens: 5 days
Maltese: Tiġieġ: 5t ijiem
English: MANUFACTURER'S BATCH NUMBER Batch <<number>>
Maltese: NUMRU TAL-LOTT TAL-MANIFATTUR Numru tal-lott: <<partijnummer>>
English: Kremer, 19889 and Hartman, 199310 & 199411 showed high levels of resistance in Pasteurella spp isolated from veal calves in the Netherlands.
Maltese: Kremer, 19889 u Hartman, 199310 & 199411 urew livelli għoljin ta' reżistenza f'Pasteurella spp iżolata mill-għoġġiela tal-vitella fil-Pajjiżi l-Baxxi.
English: • Bronchopneumonia caused by Pasteurella multocida, Streptococcus suis and Mycoplasma hyorhinis
Maltese: • Bronkopnewmonja kkawżata minn Pasteurella multocida, Streptococcus suis u Mycoplasma hyorhinis
English: • Bronchopneumonia and pleuropneumonia caused by Pasteurella spp., Streptococcus spp.,
Maltese: • Bronkopnewmonja u plewropnewmonja kkawżati minn Pasteurella spp., Streptococcus spp.,
English: mg product / kg body weight / day x
Maltese: mg prodott / kg piż tal-ġisem / jum x
English: Although not submitted by the marketing authorisation holder, information from the ARBAO-II7 project reporting on the occurrence of antimicrobial resistance among bacteria causing infections in pigs in the European Union between 2002-2004 showed levels of resistance to tetracylines in Actinobacillus pleuropneumoniae between 0 and 46.0% and in Strep. suis between 48.0 and 92.0%.
Maltese: Minkejja li ma ġietx sottomessa mid-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq, l-informazzjoni mill-proġett ARBAO-II 7 li rrapporta dwar l-okkorrenza ta' reżistenza antimikrobjali fost il-batterji li jikkawżaw l-infezzjonijiet fil-majjali fl-Unjoni Ewropea bejn l-20022004, uriet livelli ta' reżistenza għat-tetraċiklini f'Actinobacillus pleuropneumoniae ta' bejn 0 u 46.0% u fi Strep. suis ta' bejn 48.0 u 92.0%.
English: High levels of resistance to tetracyclines in swine respiratory pathogens have also been documented (ARBAO-II study, 2008)7.
Maltese: Livelli għoljin ta' reżistenza għattetraċiklini fil-patoġeni respiratorji tal-majjali kienu diġà ġew iddokumentati (studju ARBAO-II, 2008)7.
English: Cross resistance between tetracyclines has also been described.
Maltese: Ġiet deskritta wkoll il-cross resistance bejn it-tetracyclines.
English: In human medicine, doxycycline is the treatment of choice for the treatment of acute tracheobronchitis, acute bronchitis and acute bronchiolitis caused by primary bacterial infections (Mycoplasma pneumoniae, Chlamydia pneumoniae) and bacterial superinfections (Pneumococci, Haemophilus spp.).
Maltese: Fil-mediċina umana, doxycycline huwa l-kura tal-għażla għall-kura tat-trakeobronkite akuta, il-bronkite akuta u lbronkjolite akuta kkawżata minn infezzjonijiet batteriċi primarji (Mycoplasma pneumoniae, Chlamydia pneumoniae) u superinfezzjonijiet batterjali (Pneumococci, Haemophilus spp.).
English: A dose finding study by Pijpers, 1990b6, investigated the prophylactic effect of doxycycline in feed against challenge with Actinobacillus pleuropneumoniae.
Maltese: Studju ta' sejbien tad-doża minn Pijpers, 1990b6, investiga l-effett profilattiku ta' doxycycline fl-għalf kontra l-isfida b'Actinobacillus pleuropneumoniae.
English: Whereas:
Maltese: Qżieqeż:
English: Pre-ruminant calves: - Bronchopneumonia and pleuropneumonia caused by Pasteurella spp., Streptococcus spp., Arcanobacterium pyogenes, Histophilus somni and Mycoplasma spp.
Maltese: - Bronkopulmonite u plewropulmonite kkawżati mill-Pasteurella spp., Streptococcus spp., Arcanobacterium pyogenes, Histophilus somni u l-Mycoplasma spp.
English: Doxycycline hyclate 500 mg/g (equivalent to doxycycline 433 mg/g)
Maltese: Doxycycline hyclate 500 mg/g (ekwivalenti għal doxycycline 433 mg/g)
English: In a study by Goren, 19884, using a challenge infection with an E. coli strain with an MIC of 1 μg/ml, a dose related therapeutic effect was demonstrated, with moderate to good effects noticed in groups receiving doxycycline doses of 96 to 196 mg/kg body weight/day, which gave plasma concentrations of 1.7 to 3.6 μg/ml.
Maltese: Fi studju li sar minn Goren, 19884, bl-użu ta' infezzjoni ta' sfid b'razza ta' E. coli b'MIC ta' 1 μg/ml, intweriet doża relatata ma' effett terapewtiku, b'effetti minn moderati sa tajba nnutati fil-gruppi li kienu qegħdin jirċievu doxycycline f'dożi ta' 96 sa 196 mg/kg tal-piż tal-ġisem/ġurnata, li taw konċentrazzjonijiet fil-plażma ta' 1.7 sa 3.6 μg/ml.
English: When chickens are administered a dose of 25 mg doxycycline hyclate/kg bw/day for 5 days; pigs are administered 10 mg doxycycline hyclate/kg bw/day for 5 days; and calves are administered 5 mg doxycycline hyclate/kg bw, twice a day for 5 days; meat withdrawal periods of 5, 8 and 7 days respectively, will ensure consumer safety.
Maltese: Meta t-tiġieġ jingħataw doża ta' 25 mg doxycycline hyclate/kg bw/kuljum għal 5 ijiem; il-majjali jingħataw 10 mg doxycycline hyclate/kg bw/kuljum għal 5 ijiem; u l-għoġġiela jingħataw 5 mg doxycycline hyclate/kg bw, darbtejn kuljum għal 5 ijiem; il-perjodi tal-irtirar ta' 5, 8 u 7 ijiem rispettivi għal-laħam, jassiguraw is-sigurtà lill-konsumatur.
English: Data from Goren, 19831, on the in vitro susceptibility of pathogens isolated from poultry between 1978 and 1981 showed that susceptibility of P. multocida was > 70%, but that of E. coli varied between 4 to 34% over the time period studied.
Maltese: Dejta minn Goren, 19831, dwar is-suxxettibilità in vitro tal-patoġeni iżolati mit-tjur bejn l-1978 u l-1981 uriet li s-suxxettibilità ta' P. multocida kienet ta' > 70%, iżda dik ta' E. coli varjat bejn l-4 sa l-34% matul il-perjodu ta' żmien li fih ġiet studjata.
English: A study investigated the safety of Doxycyline 50% WSP administered at dose rates of 0, 10, 50 and 150 mg doxycycline hyclate/kg body weight/day for 10 days.
Maltese: Studju investiga s-sigurtà ta' Doxycyline 50% WSP li ngħata f'rati ta' doża ta' 0, 10, 50 u 150 mg doxycycline hyclate/kg tal-piż tal-ġisem/kuljum għal 10 ijiem.
English: The precautions recommended by the CVMP to limit the development of resistance, which resulted from the Article 35 referral, have been included in section 4.5 of the SPC.
Maltese: Il-prekawzjonijiet irrakkomandati mis-CVMP biex jiġi limitat l-iżvilupp ta' reżistenza, li rriżultat mirriferiment għall-Artikolu 35, ġew inklużi fis-sezzjoni 4.5 tal-SPC.
English: Belgium Dopharma Research BV Zalmweg 24
Maltese: Dopharma Research BV Zalmweg 24
English: Doxycycline hyclate: 500 mg (equivalent to 433 mg doxycycline) Excipients:
Maltese: Doxycycline hyclate: 500 mg (ewkivalenti għal 433 mg doxycycline)
English: A study investigated the safety of Doxycyline 50% WSP administered at doses of 0, 25 and 75 mg doxycycline hyclate/kg body weight /day for 5 days.
Maltese: Studju investiga s-sigurtà ta' Doxycyline 50% WSP mogħti f'dożi ta' 0, 25 u 75 mg doxycycline hyclate/kg tal-piż tal-ġisem /kuljum għal 5 ijiem.
English: Four resistance mechanisms acquired by microorganisms against tetracyclines in general have been reported: Decreased accumulation of tetracyclines (decreased permeability of the bacterial cell wall and active efflux), protein protection of the bacterial ribosome, enzymatic inactivation of the antibiotic and rRNA mutations (preventing the tetracycline binding to ribosome).
Maltese: Ġew irrapportati erba' mekkaniżmi ta' reżistenza miksubin mill-mikro-organiżmi kontra ttetracyclines inġenerali: akkumulazzjoni mnaqqsa tat-tetracyclines (permeabilità mnaqqsa tal-ħajt ċellulari batterjali u effluss attiv), protezzjoni tal-proteini tar-ribosomi batterjali, inattivazzjoni enzimatika tal-antibijotiku u mutazzjoni tal-rRNA (bir-riżultat li jkun prevenut it-tgħaqqis tattetracycline mar-ribosomi).
English: Pijpers, 1990, determined the steady-state concentration of doxycycline following oral in-feed administration at doses of 7, 13 and 26 mg/kg/body weight, twice daily.
Maltese: Pijpers, 1990, iddetermina l-konċentrazzjoni fi stat stabbli ta' doxycycline wara l-għoti fl-għalf f'dożi ta' 7, 13 u 26 mg/kg/tal-piż tal-ġisem, darbtejn kuljum.
English: A study by Kuttler, 197813 showed that doxycycline was effective in moderating anaplasmosis in splenectomised calves infected with Anaplasma marginale.
Maltese: Studju li sar minn Kuttler, 197813 wera li doxycycline kien effettiv fil-moderazzjoni tal-anaplażmożi fl-għoġġiela bi splenettomija infettati b'Anaplasma marginale.
English: Tetracyclines have broad spectrum activity inhibiting Gram-positive and Gram-negative bacteria, mycoplasmas, chlamydiae, rickettsias and some protozoa.
Maltese: Ittetraċiklini għandhom attività bi spettru wiesgħa li jinibixxu l-batterji Gram-pożittivi u Gramnegattivi, il-mycoplasmas, chlamydiae, rickettsias u ċerti protozoa.
English: Steady state plasma concentrations of 2.05 ± 0.47 μg/ml were reached within 6 hours after start of the medication and varied between 1.28 and 2.18 μg/ml with a dosage of 25 mg/kg body weight during 5 days.
Maltese: Intlaħqu konċentrazzjonijiet ta' steady state plasma ta' 2.05 ± 0.47 μg/ml f'temp ta' 6 siegħat millbidu tal-medikazzjoni u varjaw bejn 1.28 u 2.18 μg/ml b'dożaġġ ta' 25 mg/kg matul 5t ijiem.
English: Lactose
Maltese: Tiġieġ
English: Calves: 7 days Pigs: 8 days Chickens: 5 days
Maltese: Għoġġiela qabelma jibdew jixtarru: 7t ijiem Qżieqeż: 8t ijiem
English: Dis.
Maltese: Vet.
English: Do not use after the expiry date stated on the label after exp.
Maltese: Tużax wara d-data ta' skadenza li ssib fuq it-tabella, wara l-ittri “exp”.
English: In this study, doses of doxycycline equivalent to 16, 7.5 and 3.6 mg/kg body weight/day were effective in preventing disease in 6/6, 5/6 and 1/6 pigs, respectively.
Maltese: F'dan l-istudju, dożi ta' doxycycline ekwivalenti għal 16, 7.5 u 3.6 mg/kg tal-piż tal-ġisem/kuljum kienu effettivi fil-prevenzjoni tal-mard fi 6/6, 5/6 u 1/6 rispettivament, fil-majjali.
English: Not permitted for use in cattle producing milk for human consumption.
Maltese: Mhux permess fit-tjur waqt il-bidien li jipproduċu bajd għall-konsum mill-bniedem.
English: Denmark Dopharma Research B.V. Zalmweg 24
Maltese: Id-Danimarka Dopharma Research B.V. Zalmweg 24
English: In a study by Meijer, 19938, following administration of doxycycline hyclate at 5 mg/kg body weight/twice daily via milk replacer for 5 days to immature calves, plasma concentrations varied between 1.0 and 2.3 μg/ml.
Maltese: Fi studju li sar minn Meijer, 19938, wara l-għoti ta' doxycycline hyclate f'doża ta' 5 mg/kg tal-piż talġisem/darbtejn kuljum permezz ta' sostitut tal-ħalib għal 5 ijiem lill-għoġġiela żgħar, ilkonċentrazzjonijiet fil-plażma varjaw bejn 1.0 u 2.3 μg/ml.
English: In the group treated with doxycycline at 16 mg/kg body weight/day, plasma levels were between 1.28 and 1.83 μg/ml, and exceeded the MIC of the challenge strain (1 μg/ml).
Maltese: Fil-grupp li rċieva kura b' doxycycline f'doża ta' 16 mg/kg tal-piż talġisem/kuljum, il-livelli fil-plażma kienu bejn il-1.28 u 1.83 μg/ml, u ssuperaw il-MIC tar-razza bi sfida (1 μg/ml).
English: Cattle, 627-631 (1986) 13 Kuttler et al, Relative efficacy of two oxytetracycline formulations and doxycycline in the treatment of acute anaplasmosis in splenectomized calves, Am. J. Vet. Res., 39 (2), 347-349 (1978)
Maltese: Kuttler et al, Relative efficacy of two oxytetracycline formulations and doxycycline in the treatment of acute anaplasmosis in splenectomized calves, Am. J.
English: Mean plasma values of 0.44 ± 0.12 μg/ml after 3 days of medication with an average dose of 10 mg/kg body weight were found.
Maltese: 12 μg/ml wara 3t ijiem ta' medikazzjoni b'doża medja ta' 10 mg/kg.
English: The doxycycline plasma level reached an average of 2.2 to 2.5 μg/ml.
Maltese: Il-livell ta' doxycycline fil-plasma laħaq medja ta' 2.2 sa 2.5 μg/ml.
English: STATEMENT OF THE ACTIVE AND OTHER SUBSTANCES Doxycycline hyclate 500 mg/g (equivalent to doxycycline 433 mg/g)
Maltese: DIKJARAZZJONI TAS-SUSTANZA ATTIVA U SUSTANZI OĦRA Doxycycline hyclate 500 mg/g (ekwivalenti għal doxycycline 433 mg/g)
English: Tetracycline resistance is usually acquired by means of plasmids or other mobile elements (e.g. conjugative transposones).
Maltese: Ir-reżistenza għat-tetracycline normalment tinkiseb permezz tal-plasmidi jew elementi oħrajn mobbli (eż. conjugative transposones).
English: Pigs: - Atrophic rhinitis caused by Pasteurella multocida and Bordetella bronchiseptica; - Bronchopneumonia caused by Pasteurella multocida, Streptococcus suis and Mycoplasma hyorhinis; - Pleuropneumonia caused by Actinobacillus pleuropneumoniae.
Maltese: - Bronkopulomite kkawżata mill-Pasteurella multocida, Streptococcus suis u l-Mycoplasma hyorhinis; - Plewropulmonite kkawżata mill-Actinobacillus pleuropneumoniae.
English: INN & Strength
Maltese: Isem & indirizz
English: Overall summary of the scientific evaluation of Doxycycline 50% WSP and associated names (see annex I)
Maltese: Sommarju ġenerali tal-evalwazzjoni xjentifika ta' Doxycycline 50% WSP u l-ismijiet assoċjati (ara l-Anness I)
English: After a dosage of 10 mg/kg body weight /day during 5 days, an elimination halftime varying between 15 and 28 hours was found.
Maltese: Wara dożaġġ ta' 10 mg/kg/jum għal 5t ijiem, instab halftime ta' eliminazzjoni li jvarja bejn il-15 u t28 siegħa.
English: Chickens: - Infections of the respiratory tract caused by Mycoplasma spp., Escherichia coli, Haemophilus paragallinarum and Bordetella avium; - Enteritis caused by Clostridium perfringens and Clostridium colinum.
Maltese: - Infezzjonijiet tal-passaġġ tal-arja kkawżati mill-Mycoplasma spp., Escherichia coli, Haemophilus paragallinarum u l-Bordetella avium;
English: 4.9 Amounts to be administered and administration route
Maltese: .9 Doża rakkomandata u l-metodu tal-amministrazzjoni
English: A pharmacokinetic and residues study showed that at a daily dose of 10 mg doxycycline hydrochloride/kg body weight, doxycycline reached a steady state concentration of 0.4 μg/ml within 3 days.
Maltese: Studju farmakokinetiku u tar-residwi wera li f'doża ta' kuljum ta' 10 mg doxycycline hydrochloride/kg tal-piż tal-ġisem, doxycycline laħaq konċentrazzjoni fi stat stabbli ta' 0.4 μg/ml fi 3 ijiem.